a new era for treating cancer

+

Who are we?

R-nuucell is a spin-off of Faculdade de Ciências, Universidade de Lisboa (FCUL) focused on the development of new anticancer chemotherapeutics to treat metastatic cancer.

Mission and Strategy

R-nuucell's mission is to develop innovative chemotherapeutics to treat metastatic cancers. Our lead drug is protected by an international patent (WO2016/087932) and we are currently running the last assays for its in vivo proof-of-concept in a metastatic breast cancer model without clinical cure.

The treatment of metastatic and resistant cancers is an unmet medical need that R-nuucell wants to address.

The treatment of metastatic and resistant cancers is an unmet medical need that R-nuucell wants to address.

+

Challenge

Breast cancer is the second most lethal disease in women. According to World Health Organization there are 2.1 million new breast cancers per year, from which approximately half of them are metastatic cancers without specific treatment. R-nuucell aims to address this clinical need with the development of a targeted innovative chemotherapeutic agent.

Triple negative breast cancer does not answer to any of the drugs available in the market and it spreads out to other tissues (metastasize) in very early stages of the disease. Due to lack of a specific treatment, the clinical strategy consists of a broad cocktail of drugs that inevitably causes severe side effects and, in most cases, only extends patients' lives for some months.

R-nuucell is developing a chemotherapeutic agent which mechanism is related to the metastization process, thus tackling the most lethal feature of cancer: its ability to spread and metastasize.

+

Our History

2014-2018

In vitro proof-of-concept (FCT projects: IF/01302/2013; PTDC/QUI-QIN/28662/2017)

2014 2015 2016 2017 2018 2019 2020 2021
   
     
     
     
     
     
     
   
   
   

Team

Founders - Scientific Board

M. Helena Garcia, PhD

Associate Professor with habilitation, Jubilated, Faculdade de Ciências, Universidade de Lisboa and Centro Química Estrutural

Andreia Valente, PhD

Researcher at Faculdade de Ciências, Universidade de Lisboa and Centro Química Estrutural

Advisory Board

Jorge Maia Alves, PhD

Full Professor, Faculdade de Ciências' Sub-Director

Rita Tomé

FCUL Technology Transfer Office Coordinator

Management Team

Francisco Rodrigues, MBA

Manager

M. Helena Garcia, PhD

Associate Professor with habilitation, Jubilated, Faculdade de Ciências, Universidade de Lisboa and Centro Química Estrutural

Andreia Valente, PhD

Researcher at Faculdade de Ciências, Universidade de Lisboa and Centro Química Estrutural

  • Founders - Scientific Board
  • Advisory Board
  • Management Team

Publications

“Polymer “ruthenium-cyclopentadienyl” conjugates - new emerging anti-cancer drugs”

European Journal of Medicinal Chemistry 2019, 168, 373-384.

Doi: 10.1016/j.ejmech.2019.02.061
+